Heparin makes differences: a molecular dynamics simulation study on the human βII-tryptase monomer.
Yan Wang1, Qing-Chuan Zheng, Chui-Peng Kong
1State Key Laboratory of Theoretical and Computational Chemistry, Institute of Theoretical Chemistry, Jilin University, Changchun 130023, P. R. China. zhengqc@jlu.edu.cn zhanghx@mail.jlu.edu.cn.
Molecular Biosystems
|November 5, 2014
Summary
Heparin stabilizes human beta-tryptase structure through salt bridge interactions, revealing key residues for inhibitor design in inflammatory and allergy diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Human beta-tryptase (hBTM) is a mast cell enzyme crucial for inflammatory and allergy diseases.
- Heparin is known to stabilize tryptase structure and maintain its activity.
- The precise interaction between heparin and hBTM at atomic resolution remains uncharacterized.
Purpose of the Study:
- To elucidate the structure-function relationship between heparin and the human beta-tryptase monomer.
- To investigate the molecular mechanisms of heparin binding to hBTM.
- To identify key residues involved in heparin-hBTM interactions for potential therapeutic targeting.
Main Methods:
- Molecular docking simulations to predict binding modes.
- Molecular dynamics (MD) simulations to analyze structural stability and interactions.
- MM-GB/SA calculations to assess binding free energy.
- Averaged noncovalent interaction (aNCI) method for interaction visualization.
Main Results:
- Heparin binding significantly stabilizes the hBTM structure primarily via salt bridge interactions.
- A critical loop containing Arg188 and Asp189 was identified as a salt bridge intermediary.
- These residues mediate the interaction between heparin and the P1 group of the ligand (0GX), influencing its orientation.
Conclusions:
- Heparin's stabilizing effect on hBTM is mediated by specific salt bridge interactions involving key residues.
- Understanding these binding characteristics provides insights into hBTM regulation.
- This knowledge can guide the rational design of novel inhibitors for treating inflammatory and allergic conditions.
